Russell Dean Anderson, MD

Assistant Professor of Medicine
Campus mail Duke Box 3395, Durham, NC 27708
Phone (919) 934-8399
Email address russell.anderson@duke.edu

1. Cancer in the elderly
2. Lung cancer
3. Anemia
4. Computer-based medical records/medical informatics
5. Cancer prevention

For more information, see http://www.canctr.mc.duke.edu/DOORS/

Education and Training

  • Fellow, Internal Medicine, University Hospitals of Cleveland, 1987 - 1990
  • Resident, Internal Medicine, University Hospitals of Cleveland, 1985 - 1987
  • Intern, Internal Medicine, University Hospitals of Cleveland, 1984 - 1985
  • M.D., Duke University, 1984

Publications

Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.

PMID
19733251
Full Text

Sedwick, W. D., R. D. Anderson, J. Baxter, S. Donover, S. Schneiter, and M. L. Veigl. “Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.” Mutat Res 326, no. 1 (January 1995): 17–27. https://doi.org/10.1016/0027-5107(94)00155-x.

PMID
7528882
Full Text

Veigl, M. L., S. P. Donover, R. D. Anderson, L. Akst, C. E. Sedwick, and W. D. Sedwick. “Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli.” Environ Mol Mutagen 26, no. 1 (1995): 16–25. https://doi.org/10.1002/em.2850260104.

PMID
7641704
Full Text

Anderson, R. D., and N. A. Berger. “International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.” Mutat Res 309, no. 1 (August 1, 1994): 109–42. https://doi.org/10.1016/0027-5107(94)90048-5.

PMID
7519727
Full Text

Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “Excision repair reduces doxorubicin-induced genotoxicity.” Mutat Res 294, no. 3 (October 1993): 215–22. https://doi.org/10.1016/0921-8777(93)90004-z.

PMID
7692261
Full Text

Anderson, R. D., C. Y. Bao, D. T. Minnick, J. Baxter, M. L. Veigl, and W. D. Sedwick. “Sequencing of double-stranded polymerase chain reaction products for mutation analysis.” Mutat Res 288, no. 1 (July 1993): 181–85. https://doi.org/10.1016/0027-5107(93)90219-6.

PMID
7686261
Full Text

Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.” Cancer Res 51, no. 15 (August 1, 1991): 3930–37.

PMID
1855210
Scholars@Duke

Anderson, R. D., M. L. Veigl, and W. D. Sedwick. “Rapid mapping of deletion and duplication mutations by the polymerase chain reaction.” Biochem Biophys Res Commun 170, no. 2 (July 31, 1990): 416–20. https://doi.org/10.1016/0006-291x(90)92107-b.

PMID
2200400
Full Text